Treatment Resistance in Psychiatric Disorders: the Search for Biological Markers Predictive of Response to Treatment

Sponsor
Centre Hospitalier St Anne
Study ID
NCT07741981
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Bipolar Disorder (BD)
  • Catatonia
  • Obsessive Compulsive Disorder (OCD)
  • Schizophrenia
  • Treatment Resistant Depression (TRD)

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Blood sampling, lumbar puncture, stool sampling, skin microbiopsy and psychometrics scales — BIOLOGICAL
    the biomarker research involves different biological sampling : blood, stool, cerebrospinal fluid, skin

Study Details

The disruption of immune system is a key candidate in the pathogenesis of psychiatric disorders, especially those resistant to traditional treatments. Involving complex processes within the brain and peripheral immune system, inflammation may lead to imbalance of neurotransmitter systems and synaptic plasticity and directly contribute to the psychiatric symptoms observed in conditions such as depression, bipolar disorder (BD) and schizophrenia (SCZ). Studies show that treatment-resistant depression (TRD) is associated with elevated levels of inflammatory markers in the blood, which are linked to a lower response to conventional antidepressants. Interventions that modulate this inflammatory response, such as immunomodulatory treatments or therapies targeting pro-inflammatory cytokines, have demonstrated beneficial effects by reducing symptoms and improving patients' quality of life. A thorough understanding of the links between inflammation and treatment resistance therefore paves the way for innovative therapeutic strategies. These approaches could transform current practices by offering more personalized and effective solutions for patients suffering from chronic and resistant psychiatric disorders.

Key Dates

First listed
Aug 3, 2026
Start date
Jul 15, 2026
Status verified
Jun 2026
Primary completion
Oct 1, 2036
Completion
Aug 1, 2038

Study Design

Enrollment
700 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER

Arms

  • Other: OCD cohort
    Patients suffering from OCD resistant to treatments
  • Other: Catatonia cohort
    Patients suffering from resistant catatonia
  • Other: TRD cohort
    Patients suffering from treatment resistant depression (TRD)
  • Other: BD cohort
    Patients suffering from treatment resistant bipolar disorders (BD)
  • Other: Schizophrenia cohort
    Patients suffering from schizophrenia resistant to treatments

Primary Outcome Measure

Changes from inclusion (V1) in disease scale scores at the end of acute phase therapy (V3) [ Time Frame: Up to 10 weeks ]

Central Contacts

Find similar trials

Nationwide
Schizophrenia trialsPsychiatry trialsMental health trialsBehavioral health trials

Related Studies